The News
SELLAS Life Sciences has enrolled its first patient in a clinical trial for SLS009, targeting newly diagnosed first-line acute myeloid leukemia (AML) patients unlikely to benefit from standard Venetoclax/Azacitidine therapy. The study aims to enroll 80 patients across the US and Europe, with topline data expected by Q4 2026.
Why It Matters
This trial highlights the integration of predictive biomarker and AI-assisted precision medicine models in oncology, which could enhance patient selection and treatment efficacy. The outcomes may influence future AML treatment protocols and the broader application of AI in personalized medicine.
Key Evidence
The information is sourced from an official announcement reported by aktiencheck, a reliable financial news outlet.
Original Article
aktiencheck
DE source 路 Published 3d ago
https://www.aktiencheck.de/news/Artikel-SELLAS_Life_Sciences_Announces_Enrollment_of_First_Patient_Newly_Diagnosed_First_Line_AML_Trial_of_SLS009-19555187